duligotuzumab
mAbexperimentalMulti-specific
Duligotuzumab (INN) is a bispecific humanized IgG1 monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to EGFR and HER3. It is in development by Roche. Clinical development for head and neck cancer and colorectal cancer have been discontinued, but phase I trials in combination with cobimetinib are evaluating safety for treatment of solid tumors. — Wikipedia
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 9, 2010 (NCT01207323)
Timeline
Indications
Mechanism of action
ERBB3 inhibitor
EGFR inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDuligotuzumab ↗
- ChEMBLCHEMBL3137345 ↗
- ChEMBLCHEMBL2109403 ↗
Also known as
- duligotuzumab
- duligotuzumab
- mehd7945a
- mehd7945a
- rg7597
- rg-7597
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01986166 | Phase 1 | Nov 1, 2013 | Genentech |
| NCT01911598 | Phase 1 | Sep 19, 2013 | Genentech |
| NCT01652482 | Phase 2 | Oct 1, 2012 | Genentech |
| NCT01577173 | Phase 2 | Jul 1, 2012 | Genentech |
| NCT01207323 | Phase 1 | Nov 9, 2010 | Genentech |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genentech | For profit | 5 | 5 | 2 | 2010 |
1 organizations
Page 1 / 1